Frequently Asked Questions

---

GLP-1 (glucagon-like peptide-1) receptor agonists are medications designed to mimic a hormone that helps regulate appetite, blood sugar, and digestion. Common GLP-1 medications include Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro).

These medications:

• Slow gastric emptying, making you feel fuller for longer.
• Reduce appetite by acting on hunger centers in the brain.
• Improve insulin sensitivity, aiding in better blood sugar control.

Candidates typically:

• Have a BMI ≥ 27 with weight-related health conditions (e.g., diabetes, hypertension).
• Have a BMI ≥ 30 without additional conditions.
• Have no contraindications, such as a history of medullary thyroid carcinoma or severe gastrointestinal issues.

• Injection: Most GLP-1 medications are given as a weekly subcutaneous injection.
• Oral: Some formulations, like Rybelsus, are available in pill form but may have different indications.

GLP-1 medications are generally safe when prescribed and monitored by a healthcare provider.

Common side effects include:

• Nausea, vomiting, diarrhea, or constipation.
• Fatigue or dizziness.
• Rare but serious side effects: pancreatitis, gallstones, or allergic reactions.

Compounding involves creating a customized medication by combining or adjusting FDA-approved ingredients. Compounded versions of Semaglutide and Tirzepatide may be offered as a more affordable alternative to brand-name medications, especially when insurance does not cover the branded options.

Patients who:

• Cannot afford brand-name medications.
• Require a customized dose not commercially available.
• Need access during shortages of branded products.

The compounding pharmacies that we source our compounded medications through are accredited by the Pharmacy Compounding Accreditation Board (PCAB) and have been used by our staff to assure effectiveness. 

Yes, switching is possible but should be done under medical supervision. 

While no specific diet is required, we recommend:

• Prioritizing high-protein and fiber-rich foods.
• Avoiding high-fat and highly processed meals, which may exacerbate side effects.
• Staying hydrated throughout the day.

• Have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Have severe gastrointestinal disease, such as gastroparesis.
• Are pregnant, breastfeeding, or planning to become pregnant.

While the FDA has recently stated that Monjouro (Tirzepatide) and Ozempic/Wegovy (Semaglutide) is readily available and is no longer in shortage. There are multiple lawsuits that are challenging this claim and our team is monitoring the situation closely. 

During your initial consultation:

• A detailed medical history and physical assessment will be completed.
• Lab work may be ordered to evaluate your overall health and identify any contraindications.
• A customized treatment plan will be created based on your goals and medical needs.

Most patients notice appetite suppression within a few days. however, The first month of medications are not expected to have any weight loss as they are at sub-theraputic levels to minimize side effects. Significant weight loss often occurs after 8–12 weeks of consistent use when paired with lifestyle changes

Our clinic offers:

• Regular follow-ups to monitor progress and adjust dosages.
• Nutrition counseling to optimize your dietary habits.
• Access to healthcare professionals for any questions or concerns.

Contact our clinic to schedule an initial consultation. We’ll assess your eligibility, discuss your goals, and develop a personalized plan to support your weight loss journey.